Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Abarbanel Mental Health Center |
---|---|
Information provided by: | Abarbanel Mental Health Center |
ClinicalTrials.gov Identifier: | NCT00305500 |
Objectives: To evaluate tolerability and efficacy of escitalopram treatment in high dose than 20-50 mg/d in out-patients with OCD Type of the study: Open label, prospective study.
Number of patients: 100 patients with OCD
Duration of the study: 18-weeks of active treatment, 8-visits:
Dose titration:
One week of 10mg Four weeks of 20mg After 4 weeks of 20mg treatment– if partial/no response, according to YBOCS score and clinical judgment, dose increase of up to 50mg depending on response, adverse events, patient preference and judgment of the clinician 12 weeks follow up on high dose. Total of 18 weeks of follow-up.
Condition | Intervention | Phase |
---|---|---|
Obsessive-Compulsive Disorder |
Drug: escitalopram |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase III Open Study of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder in Adults |
Estimated Enrollment: | 100 |
Study Start Date: | March 2006 |
Estimated Study Completion Date: | December 2006 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | EscitaHD001 |
Study First Received: | March 21, 2006 |
Last Updated: | July 25, 2006 |
ClinicalTrials.gov Identifier: | NCT00305500 |
Health Authority: | Israel: Ministry of Health |
OCD Escitalopram |
Anxiety Disorders Mental Disorders Dexetimide |
Citalopram Serotonin Obsessive-Compulsive Disorder |
Parasympatholytics Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Molecular Mechanisms of Pharmacological Action Cholinergic Antagonists Anti-Dyskinesia Agents Physiological Effects of Drugs Psychotropic Drugs Antiparkinson Agents Cholinergic Agents |
Serotonin Uptake Inhibitors Pharmacologic Actions Muscarinic Antagonists Serotonin Agents Pathologic Processes Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |